bumetanide has been researched along with Absence Seizure in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 9.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 9.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "Recent experimental data suggest bumetanide as a possible therapeutic option in newborn infants with seizures after birth asphyxia." | 9.22 | Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ( Blennow, M; Boylan, G; Chiron, C; Jullien, V; Marlow, N; Pons, G; Pressler, RM, 2016) |
| "Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment for neonatal seizures." | 9.20 | Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. ( Blennow, M; Boylan, GB; Chiron, C; Cross, JH; de Vries, LS; Hallberg, B; Hellström-Westas, L; Jullien, V; Livingstone, V; Mangum, B; Marlow, N; Murphy, B; Murray, D; Pons, G; Pressler, RM; Rennie, J; Swarte, R; Toet, MC; Vanhatalo, S; Zohar, S, 2015) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 8.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "Kaila, Löscher, and colleagues report that phenobarbital (PHB) and midazolam (MDZ) attenuate neonatal seizures following birth asphyxia, but the former only when applied before asphyxia and the latter before or after the triggering insult." | 8.02 | Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. ( Ben-Ari, Y; Delpire, E, 2021) |
| "Bumetanide was suggested as an adjunct to phenobarbital for suppression of neonatal seizures." | 8.02 | A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. ( Gailus, B; Gericke, B; Johne, M; Käufer, C; Löscher, W; Römermann, K, 2021) |
| "Our data demonstrate an anticonvulsant effect of bumetanide on KA-induced seizures in adult mice, suggesting a role for chloride plasticity in seizure progression." | 7.83 | Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. ( Maguire, J; Sivakumaran, S, 2016) |
| " The aim of this study is to evaluate the long-term effects of bumetanide, a NKCC1 inhibitor, on hippocampal neurogenesis and seizure susceptibility in hypoxia-induced neonatal seizure model." | 7.81 | In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures. ( Song, CG; Wang, S; Xiao, T; Zhang, XQ; Zhao, CS; Zhao, M; Zhu, G, 2015) |
| " The most common cause of neonatal seizures is hypoxic encephalopathy, and here we show in an established model of neonatal hypoxia-induced seizures that the NKCC1 inhibitor, bumetanide, in combination with phenobarbital is significantly more effective than phenobarbital alone." | 7.79 | Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. ( Berry, G; Cleary, RT; Huynh, T; Jackson, M; Jensen, FE; Kahle, KT; Li, Y; Manning, SM; Rakhade, SN; Rotenberg, A; Sun, H; Talos, DM, 2013) |
| "Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3." | 7.01 | A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. ( Bergin, AM; Dong, M; Fortuno, CR; Hayes, B; Jensen, FE; Krishnamoorthy, K; O'Reilly, D; Rofeberg, V; Singh, A; Soul, JS; Staley, KJ; Stopp, C; Vinks, AA; Wypij, D, 2021) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 5.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 5.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "In rat pups with early-life seizures, field recordings from dorsal and ventral hippocampus and prefrontal cortex demonstrated marked increase in coherence as well as a decrease in voltage correlation at all bandwidths compared to controls while there were minimal differences in total power and relative power spectral densities." | 5.42 | Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide. ( Barry, J; Camp, D; Flynn, S; Hernan, AE; Holmes, GL; Tian, C, 2015) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 5.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "Recent experimental data suggest bumetanide as a possible therapeutic option in newborn infants with seizures after birth asphyxia." | 5.22 | Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ( Blennow, M; Boylan, G; Chiron, C; Jullien, V; Marlow, N; Pons, G; Pressler, RM, 2016) |
| "Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment for neonatal seizures." | 5.20 | Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. ( Blennow, M; Boylan, GB; Chiron, C; Cross, JH; de Vries, LS; Hallberg, B; Hellström-Westas, L; Jullien, V; Livingstone, V; Mangum, B; Marlow, N; Murphy, B; Murray, D; Pons, G; Pressler, RM; Rennie, J; Swarte, R; Toet, MC; Vanhatalo, S; Zohar, S, 2015) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 4.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "Kaila, Löscher, and colleagues report that phenobarbital (PHB) and midazolam (MDZ) attenuate neonatal seizures following birth asphyxia, but the former only when applied before asphyxia and the latter before or after the triggering insult." | 4.02 | Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. ( Ben-Ari, Y; Delpire, E, 2021) |
| "Bumetanide was suggested as an adjunct to phenobarbital for suppression of neonatal seizures." | 4.02 | A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. ( Gailus, B; Gericke, B; Johne, M; Käufer, C; Löscher, W; Römermann, K, 2021) |
| " In pentylenetetrazole-induced acute seizures only BUM532 combined with a sub-effective dose of PB increased the seizure threshold." | 3.96 | Functional characterization of novel bumetanide derivatives for epilepsy treatment. ( Auer, T; Erker, T; Schreppel, P; Schwarzer, C, 2020) |
| "Based on the potential role of Na-K-Cl cotransporters (NKCCs) in epileptic seizures, the loop diuretic bumetanide, which blocks the NKCC1 isoforms NKCC1 and NKCC2, has been tested as an adjunct with phenobarbital to suppress seizures." | 3.88 | Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy. ( Brandt, C; Feit, PW; Hampel, P; Kaila, K; Kalesse, M; Kipper, A; Löscher, W; Lykke, K; MacAulay, N; Paavilainen, P; Puskarjov, M; Römermann, K; Seja, P; Spoljaric, I; Toft-Bertelsen, TL; Töllner, K, 2018) |
| "Our data demonstrate an anticonvulsant effect of bumetanide on KA-induced seizures in adult mice, suggesting a role for chloride plasticity in seizure progression." | 3.83 | Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. ( Maguire, J; Sivakumaran, S, 2016) |
| " The aim of this study is to evaluate the long-term effects of bumetanide, a NKCC1 inhibitor, on hippocampal neurogenesis and seizure susceptibility in hypoxia-induced neonatal seizure model." | 3.81 | In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures. ( Song, CG; Wang, S; Xiao, T; Zhang, XQ; Zhao, CS; Zhao, M; Zhu, G, 2015) |
| " The most common cause of neonatal seizures is hypoxic encephalopathy, and here we show in an established model of neonatal hypoxia-induced seizures that the NKCC1 inhibitor, bumetanide, in combination with phenobarbital is significantly more effective than phenobarbital alone." | 3.79 | Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. ( Berry, G; Cleary, RT; Huynh, T; Jackson, M; Jensen, FE; Kahle, KT; Li, Y; Manning, SM; Rakhade, SN; Rotenberg, A; Sun, H; Talos, DM, 2013) |
| " Seizures were induced by the volatile convulsant agent flurothyl." | 3.77 | Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats. ( Khazipov, R; Minlebaev, M, 2011) |
| "The obtained results provide further evidence that bumetanide may be beneficial for treating neonatal seizures, and that NKCC1 represents a potential target for antiepileptic interventions in the immature brain." | 3.75 | Bumetanide inhibits rapid kindling in neonatal rats. ( Mazarati, A; Sankar, R; Shin, D, 2009) |
| "Phenobarbital failed to abolish or depress recurrent seizures in 70% of hippocampi." | 3.74 | Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. ( Brumback, AC; Dzhala, VI; Staley, KJ, 2008) |
| " We report that application of 4-aminopyridine (4-AP) to immature (P6-P9) neocortical slices generates layer-specific interictal seizures (IISs) that transform after recurrent seizures to ictal seizures (ISs)." | 3.74 | Layer-specific generation and propagation of seizures in slices of developing neocortex: role of excitatory GABAergic synapses. ( Ben-Ari, Y; Represa, A; Rheims, S; Zilberter, Y, 2008) |
| "The purpose of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, which block the KCC1 potassium-chloride transporter in the kidney loop of Henle and the KCC2 potassium-chloride transporter in neuronal membranes, would prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats." | 3.70 | Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. ( Guo, SZ; Iyer, VG; Reid, KH, 2000) |
| "Total seizure burden varied widely, with much higher seizure burden in treatment versus control groups (median = 3." | 3.01 | A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. ( Bergin, AM; Dong, M; Fortuno, CR; Hayes, B; Jensen, FE; Krishnamoorthy, K; O'Reilly, D; Rofeberg, V; Singh, A; Soul, JS; Staley, KJ; Stopp, C; Vinks, AA; Wypij, D, 2021) |
| "According to our results, seizure frequency was reduced considerably in these patients." | 2.78 | Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. ( Beladimoghadam, N; Eftekhari, S; Gharakhani, M; Hadjighassem, MR; Hashemi Fesharaki, SS; Joghataei, MT; Mehvari Habibabadi, J; Mostafavi, H; Najafi Ziarani, M; Rahimian, E, 2013) |
| "Seizures are a common manifestation of acute neurologic insults in neonates and are often resistant to the standard antiepileptic drugs that are efficacious in children and adults." | 2.50 | Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. ( Kahle, KT; Kaila, K; Puskarjov, M; Ruusuvuori, E, 2014) |
| "Levetiracetam has been used in children and infants with good efficacy, an excellent safety profile, and near-ideal pharmacokinetic characteristics." | 2.49 | Newly emerging therapies for neonatal seizures. ( Mangum, B; Pressler, RM, 2013) |
| "Epilepsy was induced by pilocarpine, which was shown to produce long-lasting increases in NKCC1 in the hippocampus, whereas MEST did not alter NKCC1 mRNA in this region." | 1.62 | Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice. ( Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K, 2021) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 1.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "Male pups showed more severe seizure-like activities than female pups in P4-P6 under etomidate anesthesia." | 1.51 | Role of estradiol in mediation of etomidate-caused seizure-like activity in neonatal rats. ( Li, C; Lu, X; Sun, J; Yang, C, 2019) |
| "Controlling seizures remains a challenging issue for the medical community." | 1.51 | Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue. ( Carlen, PL; Chang, M; Dufour, S; Valiante, TA, 2019) |
| "Understanding the seizure-inducing mechanisms of TBI is of the utmost importance, because these seizures are often resistant to traditional first- and second-line anti-seizure treatments." | 1.46 | NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility. ( Cotrina, ML; Gu, S; He, X; Huang, JH; Liu, W; Nedergaard, M; Shapiro, LA; Wang, EW; Wang, F; Wang, W; Wang, X, 2017) |
| "In rat pups with early-life seizures, field recordings from dorsal and ventral hippocampus and prefrontal cortex demonstrated marked increase in coherence as well as a decrease in voltage correlation at all bandwidths compared to controls while there were minimal differences in total power and relative power spectral densities." | 1.42 | Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide. ( Barry, J; Camp, D; Flynn, S; Hernan, AE; Holmes, GL; Tian, C, 2015) |
| "A high incidence of seizures occurs during the neonatal period when immature networks are hyperexcitable and susceptible to hypersyncrhonous activity." | 1.37 | Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. ( Kriegstein, AR; Wang, DD, 2011) |
| "Neonatal seizures have devastating consequences for brain development and are inadequately treated by available antiepileptics." | 1.35 | Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. ( Barnett, SM; Kahle, KT; Sassower, KC; Staley, KJ, 2009) |
| "Electroclinical uncoupling of neonatal seizures refers to electrographic seizure activity that is not clinically manifest." | 1.35 | Differences in cortical versus subcortical GABAergic signaling: a candidate mechanism of electroclinical uncoupling of neonatal seizures. ( Augustine, G; Bacskai, BJ; Dzhala, VI; Feng, G; Glykys, J; Kuchibhotla, KV; Kuner, T; Staley, KJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (22.00) | 29.6817 |
| 2010's | 25 (50.00) | 24.3611 |
| 2020's | 13 (26.00) | 2.80 |
| Authors | Studies |
|---|---|
| Staley, KJ | 7 |
| Kaila, K | 5 |
| Löscher, W | 8 |
| Welzel, B | 1 |
| Johne, M | 4 |
| Rao, S | 1 |
| Farhat, A | 1 |
| Rakshasbhuvankar, A | 1 |
| Athikarisamy, S | 1 |
| Ghosh, S | 1 |
| Nagarajan, L | 1 |
| Auer, T | 1 |
| Schreppel, P | 1 |
| Erker, T | 1 |
| Schwarzer, C | 1 |
| Soul, JS | 1 |
| Bergin, AM | 1 |
| Stopp, C | 1 |
| Hayes, B | 1 |
| Singh, A | 1 |
| Fortuno, CR | 1 |
| O'Reilly, D | 1 |
| Krishnamoorthy, K | 1 |
| Jensen, FE | 3 |
| Rofeberg, V | 1 |
| Dong, M | 1 |
| Vinks, AA | 1 |
| Wypij, D | 1 |
| Römermann, K | 5 |
| Hampel, P | 4 |
| Gailus, B | 3 |
| Theilmann, W | 1 |
| Ala-Kurikka, T | 1 |
| Gramer, M | 1 |
| Gericke, B | 2 |
| Kaczmarek, E | 1 |
| Ben-Ari, Y | 4 |
| Delpire, E | 2 |
| Käufer, C | 1 |
| Ragot, A | 1 |
| Luhmann, HJ | 1 |
| Dipper-Wawra, M | 1 |
| Heinemann, U | 2 |
| Holtkamp, M | 1 |
| Fidzinski, P | 1 |
| Brandt, C | 1 |
| Seja, P | 1 |
| Töllner, K | 1 |
| Kalesse, M | 1 |
| Kipper, A | 1 |
| Feit, PW | 1 |
| Lykke, K | 1 |
| Toft-Bertelsen, TL | 1 |
| Paavilainen, P | 1 |
| Spoljaric, I | 1 |
| Puskarjov, M | 2 |
| MacAulay, N | 1 |
| Chang, M | 1 |
| Dufour, S | 1 |
| Carlen, PL | 1 |
| Valiante, TA | 1 |
| Yuan, Y | 1 |
| O'Malley, HA | 1 |
| Smaldino, MA | 1 |
| Bouza, AA | 1 |
| Hull, JM | 1 |
| Isom, LL | 1 |
| Yang, C | 1 |
| Li, C | 1 |
| Sun, J | 1 |
| Lu, X | 1 |
| Cleary, RT | 1 |
| Sun, H | 1 |
| Huynh, T | 1 |
| Manning, SM | 1 |
| Li, Y | 1 |
| Rotenberg, A | 1 |
| Talos, DM | 2 |
| Kahle, KT | 4 |
| Jackson, M | 1 |
| Rakhade, SN | 1 |
| Berry, G | 2 |
| Pressler, RM | 4 |
| Mangum, B | 3 |
| Ruusuvuori, E | 1 |
| Wang, S | 1 |
| Zhang, XQ | 1 |
| Song, CG | 1 |
| Xiao, T | 1 |
| Zhao, M | 1 |
| Zhu, G | 1 |
| Zhao, CS | 1 |
| MacKenzie, G | 1 |
| Maguire, J | 2 |
| Glass, HC | 1 |
| Boylan, GB | 2 |
| Marlow, N | 3 |
| Blennow, M | 3 |
| Chiron, C | 3 |
| Cross, JH | 2 |
| de Vries, LS | 3 |
| Hallberg, B | 2 |
| Hellström-Westas, L | 3 |
| Jullien, V | 3 |
| Livingstone, V | 1 |
| Murphy, B | 2 |
| Murray, D | 2 |
| Pons, G | 3 |
| Rennie, J | 2 |
| Swarte, R | 1 |
| Toet, MC | 2 |
| Vanhatalo, S | 2 |
| Zohar, S | 2 |
| Holmes, GL | 1 |
| Tian, C | 1 |
| Hernan, AE | 1 |
| Flynn, S | 1 |
| Camp, D | 1 |
| Barry, J | 1 |
| Thoresen, M | 1 |
| Sabir, H | 1 |
| Boylan, G | 1 |
| Sivakumaran, S | 1 |
| Tao, K | 1 |
| Ichikawa, J | 1 |
| Matsuki, N | 1 |
| Ikegaya, Y | 1 |
| Koyama, R | 1 |
| Wang, F | 1 |
| Wang, X | 1 |
| Shapiro, LA | 1 |
| Cotrina, ML | 1 |
| Liu, W | 1 |
| Wang, EW | 1 |
| Gu, S | 1 |
| Wang, W | 1 |
| He, X | 1 |
| Nedergaard, M | 1 |
| Huang, JH | 1 |
| Hu, JJ | 1 |
| Yang, XL | 1 |
| Luo, WD | 1 |
| Han, S | 1 |
| Yin, J | 1 |
| Liu, WH | 1 |
| He, XH | 1 |
| Peng, BW | 1 |
| Mazarati, A | 1 |
| Shin, D | 1 |
| Sankar, R | 1 |
| Nardou, R | 1 |
| Khalilov, I | 1 |
| Barnett, SM | 1 |
| Sassower, KC | 1 |
| Glykys, J | 1 |
| Dzhala, VI | 3 |
| Kuchibhotla, KV | 1 |
| Feng, G | 1 |
| Kuner, T | 1 |
| Augustine, G | 1 |
| Bacskai, BJ | 1 |
| Wang, DD | 1 |
| Kriegstein, AR | 1 |
| Wahab, A | 1 |
| Albus, K | 1 |
| Minlebaev, M | 1 |
| Khazipov, R | 1 |
| Chabwine, JN | 1 |
| Vanden Eijnden, S | 1 |
| Eftekhari, S | 1 |
| Mehvari Habibabadi, J | 1 |
| Najafi Ziarani, M | 1 |
| Hashemi Fesharaki, SS | 1 |
| Gharakhani, M | 1 |
| Mostafavi, H | 1 |
| Joghataei, MT | 1 |
| Beladimoghadam, N | 1 |
| Rahimian, E | 1 |
| Hadjighassem, MR | 1 |
| Sdrulla, DA | 1 |
| Brumback, AC | 2 |
| Mathews, GC | 1 |
| Benke, TA | 1 |
| Fukuda, A | 1 |
| Rheims, S | 1 |
| Represa, A | 1 |
| Zilberter, Y | 1 |
| Reid, KH | 1 |
| Guo, SZ | 1 |
| Iyer, VG | 1 |
| Brown, RD | 1 |
| Feldman, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent[NCT01434225] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures[NCT00830531] | Phase 1 | 43 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for bumetanide and Absence Seizure
| Article | Year |
|---|---|
Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies.
Topics: Aminoglycosides; Animals; Anticonvulsants; Bumetanide; Epilepsy; Hearing Loss; Humans; Infant; Infan | 2023 |
Newly emerging therapies for neonatal seizures.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Child Development; Epilepsy; Fructose; Humans; Infant, | 2013 |
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.
Topics: Anticonvulsants; Brain; Bumetanide; Humans; Infant, Newborn; Infant, Newborn, Diseases; K Cl- Cotran | 2014 |
The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
Topics: Animals; Bumetanide; Drug Delivery Systems; Epilepsy, Benign Neonatal; Humans; Infant, Newborn; Seiz | 2008 |
Blocking seizures with the diuretic bumetanide: promises and pitfalls.
Topics: Animals; Anticonvulsants; Bumetanide; Diuretics; Humans; Neurons; Patch-Clamp Techniques; Seizures | 2012 |
Pharmacology of hearing and ototoxicity.
Topics: Adrenal Glands; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bumetanid | 1978 |
5 trials available for bumetanide and Absence Seizure
| Article | Year |
|---|---|
Clarifications regarding bumetanide for neonatal seizures.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.
Topics: Anticonvulsants; Bumetanide; Double-Blind Method; Drug Therapy, Combination; Electroencephalography; | 2021 |
Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.
Topics: Bumetanide; Drug Administration Schedule; Drug Synergism; Early Termination of Clinical Trials; Feas | 2015 |
Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures.
Topics: Anticonvulsants; Asphyxia; Bumetanide; Female; Hearing Loss; Humans; Infant, Newborn; Male; Models, | 2016 |
Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy.
Topics: Adult; Anticonvulsants; Bumetanide; Electroencephalography; Epilepsy, Temporal Lobe; Humans; Male; S | 2013 |
39 other studies available for bumetanide and Absence Seizure
| Article | Year |
|---|---|
Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Topics: Animals; Anticonvulsants; Asphyxia; Asphyxia Neonatorum; Bumetanide; Epilepsy; Humans; Infant, Newbo | 2023 |
Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Bumetanide; Convulsants; Disease Models, Anima | 2020 |
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Bumetanide; Disease Models, Animal; | 2021 |
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Topics: Animals; Brain; Bumetanide; Endothelial Cells; Humans; Mice; Seizures; Sodium Potassium Chloride Sym | 2021 |
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbit | 2021 |
Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.
Topics: Animals; Anticonvulsants; Bumetanide; Epilepsy; Humans; Midazolam; Phenobarbital; Prohibitins; Seizu | 2021 |
Reply to the commentary by Ben-Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality.
Topics: Animals; Bumetanide; Epilepsy; Rats; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solut | 2021 |
A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Benzylamines; Brain; Bumetanide; Do | 2021 |
Pathology-selective antiepileptic effects in the focal freeze-lesion rat model of malformation of cortical development.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bumetanide; Cerebral Cortex; Cryosurgery; Male; Malformat | 2021 |
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Topics: Animals; Anticonvulsants; Benzylamines; Brain; Bumetanide; Drug Evaluation, Preclinical; Drug Synerg | 2018 |
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue.
Topics: Action Potentials; Animals; Bumetanide; Disease Models, Animal; Humans; Magnesium; Mice, Inbred C57B | 2019 |
Delayed maturation of GABAergic signaling in the Scn1a and Scn1b mouse models of Dravet Syndrome.
Topics: Animals; Bumetanide; Death, Sudden; Disease Models, Animal; Epilepsies, Myoclonic; Epilepsy; gamma-A | 2019 |
Role of estradiol in mediation of etomidate-caused seizure-like activity in neonatal rats.
Topics: Anesthetics, Intravenous; Animals; Brain; Bumetanide; Electroencephalography; Estradiol; Estrogen Re | 2019 |
Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
Topics: Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Brain; Bumetanide; CA1 Region, Hippoca | 2013 |
In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Topics: Animals; Animals, Newborn; Brain; Brain Chemistry; Bumetanide; Cell Proliferation; Dentate Gyrus; El | 2015 |
Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.
Topics: Acute Disease; Animals; Bumetanide; Chronic Disease; Corticosterone; Disease Models, Animal; gamma-A | 2015 |
Bumetanide for treatment of seizures in neonates.
Topics: Bumetanide; Female; Humans; Hypoxia-Ischemia, Brain; Male; Phenobarbital; Seizures | 2015 |
Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain; Bumetanide; Cell Count; Disease | 2015 |
Epilepsy: Neonatal seizures still lack safe and effective treatment.
Topics: Bumetanide; Female; Humans; Hypoxia-Ischemia, Brain; Male; Phenobarbital; Seizures | 2015 |
Bumetanide for neonatal seizures-back from the cotside.
Topics: Bumetanide; Female; Humans; Hypoxia-Ischemia, Brain; Male; Phenobarbital; Seizures | 2015 |
Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Diazepam; Disease Progression; Drug Resistant Epilepsy; | 2016 |
Experimental febrile seizures induce age-dependent structural plasticity and improve memory in mice.
Topics: Aging; Animals; Bumetanide; Disease Models, Animal; Fever; Hippocampus; Memory; Mice; Neurogenesis; | 2016 |
NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility.
Topics: Ammonia; Animals; Animals, Newborn; Bumetanide; Cell Count; Cerebral Cortex; Disease Models, Animal; | 2017 |
Bumetanide reduce the seizure susceptibility induced by pentylenetetrazol via inhibition of aberrant hippocampal neurogenesis in neonatal rats after hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Cell Movement; Cell Proliferation; Electroen | 2017 |
Bumetanide inhibits rapid kindling in neonatal rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Disease Models, Animal; Electric Stimulation | 2009 |
Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Animals, Newborn; Bicuculline; Bio | 2009 |
Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1.
Topics: Brain; Bumetanide; Electroencephalography; Female; Humans; Infant; Seizures; Sodium Potassium Chlori | 2009 |
Bumetanide for neonatal seizures: Based on evidence or enthusiasm?
Topics: Bumetanide; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Seizures; Sodium Potassium Chl | 2009 |
Differences in cortical versus subcortical GABAergic signaling: a candidate mechanism of electroclinical uncoupling of neonatal seizures.
Topics: Amygdala; Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Chlorides; Female; gamma-Aminobuty | 2009 |
Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits.
Topics: Animals; Bumetanide; Cerebral Cortex; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; I | 2011 |
Age- and region-specific effects of anticonvulsants and bumetanide on 4-aminopyridine-induced seizure-like events in immature rat hippocampal-entorhinal cortex slices.
Topics: 4-Aminopyridine; Action Potentials; Age Factors; Animals; Animals, Newborn; Anticonvulsants; Bumetan | 2011 |
Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats.
Topics: 3-Hydroxybutyric Acid; Animals; Animals, Suckling; Anticonvulsants; Brain; Bumetanide; Convulsants; | 2011 |
A claim for caution in the use of promising bumetanide to treat neonatal seizures.
Topics: Bumetanide; Humans; Infant; Seizures; Sodium Potassium Chloride Symporter Inhibitors | 2011 |
NKCC1 transporter facilitates seizures in the developing brain.
Topics: Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Cerebral Cortex; Diuretics; Electroencephalo | 2005 |
Diuretic soothes seizures in newborns.
Topics: Animals; Bumetanide; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Infant, Newbo | 2005 |
Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Topics: Animals; Anticonvulsants; Bumetanide; Chloride Channels; Chlorides; Drug Synergism; Drug Therapy, Co | 2008 |
Layer-specific generation and propagation of seizures in slices of developing neocortex: role of excitatory GABAergic synapses.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Animals; Animals, Newborn; | 2008 |
Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats.
Topics: Acoustic Stimulation; Animals; Auditory Pathways; Brain; Bumetanide; Carrier Proteins; Diuretics; Ep | 2000 |